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Abstract
In systemic sclerosis (SSc), there is no proven treatment to prevent
disease progression. In a recent meta-analysis of three randomised
controlled trials (RCTs) and six open prospective studies on
cyclophosphamide (CYC), no significant changes in lung function
were observed. However, CYC is associated with an improvement
of Mahler’s dyspnea index, short form-36 (physical and mental
domains), and health-related quality of life, contributing to the
amelioration of patients’ functional status. Further RCTs on early
SSc are needed to assess the real efficacy of CYC in inducing
remission and increasing survival.
In a previous issue of Arthritis Research & Therapy, Nannini
and colleagues [1] addressed the topic by a well-conducted
meta-analysis and concluded that cyclophosphamide (CYC)
treatment does not induce a statistically significant improve-
ment in lung function in systemic sclerosis (SSc) interstitial
lung disease (ILD). This meta-analysis pooled the data from
three randomised controlled trials (RCTs) and six obser-
vational studies and focused on the changes in pulmonary
functional parameters (forced vital capacity [FVC] and diffus-
ing lung capacity for carbon monoxide [DLCO]) of SSc
patients treated with CYC for at least 1 year [1]. Such a
conclusion sets a negative scenario in which CYC should not
be considered as an ‘anchor’ drug for the treatment of SSc
and ILD.
In SSc, no drug or combination of drugs has been demon-
strated to modify disease progression. In both RCTs versus
placebo, the trend toward improvement in FVC suggests that
the efficacy of CYC on lung function is limited, as also
corroborated by a mild effect size (Table 1) [2,3]. This
negative opinion may not reflect what is going on in a ‘real
life’ scenario, when other efficacy parameters are considered.
Actually, the scleroderma lung study group reported, after
12 months, a significant reduction of Mahler’s dyspnea index
in CYC-treated patients when compared with placebo
(P <0.0001) and a statistically significant amelioration of
short form-36 (SF-36) in each domain: mental (P = 0.006),
emotional (P = 0.005), general health status (P = 0.003), and
vitality (P = 0.009) [4]. Despite the negligible value of effect
size for all of these scale domains, minimum clinically
important difference (which represents the smallest improve-
ment in the score of a health-related quality of life measure-
ment instrument which patients perceive as beneficial) was
significantly higher for all measures in CYC-treated patients
[5]. The improvement of dyspnea and reduction of skin
thickness may have a favourable effect not only on functional
status but also on psychological aspects, as demonstrated by
the analysis of each SF-36 domain.
In SSc, the efficacy of CYC is an important issue and
therefore attention needs to be focused on some clinical
facts that are observed in ‘real life’ in everyday practice. The
first fact is that, when ILD is treated in an advanced phase, no
drug has been able to ‘clean’ the lung, reverting fibrosis into a
normal parenchyma. Actually, in most studies carried out in
patients with long-lasting disease, CYC has been able to
‘freeze’ the disease process. For a disease such as SSc, in
which ‘everything (or nothing) seems to work’ [6], this may be
considered a positive result that should encourage physicians
to move the use of CYC to the earliest phase of SSc, before
fibrosis does consistent damage in the interstitial
compartment. The second fact is that the identification of
early pulmonary disease remains a problem because the tools
used so far may be inadequate. On high-resolution computed
tomography, a ground-glass appearance of lower lobes can
reflect the presence of a thin yet irreversible fibrosis [7].
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Moreover, neither bronchoalveolar lavage findings nor their
changes after CYC treatment may predict the response to
CYC [8]. In this condition, the best available way to identify
active and reversible disease seems to be the identification of
Table 1
Primary and secondary outcomes in three randomised controlled trials and corresponding effect sizes
Reference Outcomes Effect size Safety
1. Hoyles, et al. [3], Follow-up after 1 year 3 withdrawals in the active group due 
2006 Primary endpoints: to side effects (1 patient had 
FVC: no change P = 0.08 versus placebo ES = 0.35 (CI –0.24, 0.94) intolerable nausea and 1 patient had 
DLCO: no change P = 0.64 versus placebo ES = –0.01 (CI –0.59, 0.58) abnormal findings on liver function 
TLC: no change P = 0.61 ES = 0.06 (CI –0.53, 0.64) tests during treatment with AZA) and 
FEV1: no change P = 0.16 ES = 0.28 (CI –0.31, 0.86) no withdrawals in the placebo group 
Kco: no change ES = 0.3 (CI –0.29, 0.88) (NNH = 11)
Secondary endpoint:
HRCT: trends toward to improve P = 0.39 NNT = 5
2. Tashkin, et al. [2], Skin score: decreased ES = –0.24 (CI 0.09, – 0.56) 20 patients withdrew in the active 
2006 Diffuse ES = –0.06 (CI 0.27, – 0.38) group and 13 patients in the placebo 
Limited ES = –0.04 (CI 0.28, –0.37) group, mostly due to adverse events 
or serious adverse events within 
Primary outcome: 12 months.
FVC: increased (P <0.03) favouring Cyc ES = 0.14 (CI –0.18, 0.47) (NNH = 11.2)
Secondary outcomes:
TLC: increased (P = 0.026) favouring Cyc ES = 0.19 (CI –0.13, 0.52)
DLCO: no change ES = –0.06 (CI –0.38, 0.27)
SF-36 score:
Physical: no change versus placebo ES = 0.24 (CI –0.09, 0.56)
Mental: no change versus placebo ES = 0.27 (CI –0.06, 0.6)
HAQ-DI: decreased ES = –0.37 (CI –0.04, – 0.69)
Transitional dyspnea score: improvement Not possible to calculate
P <0.001
3. Nadashkevich, MRSS: decreased after 12 (P <0.001) ES = –1.31 (CI –0.74, –1.85) No withdrawals
et al. [11], 2006 and 18 months (P <0.01) of therapy in after 6 months Adverse events on Cyc included hair 
Cyc group versus baseline; P <0.001 ES = –5.94 (CI –4.7, –7.03) loss, nausea, dyspepsia, and 
versus controlled patients after 12 months leucopenia.
ES = –9.21 (CI –7.39, –10.79) 
after 18 months
Attack frequency of Raynaud: decreased ES = –1.99 (CI –1.34, – 2.58) 
after 12 (P <0.001) and 18 months after 6 months
(P <0.01) of therapy in Cyc group versus ES = –8.35 (CI –6.69, –9.81) 
baseline; P <0.001 versus controlled after 12 months
patients ES = –11.68 (CI –9.41, –13.66) 
after 18 months NNT = 1.3
FVC: no change in Cyc group (P = NS), ES = 3.38 (CI 2.56, 4.12) 
worsening in AZA group (P <0.01) after after 6 months
6, 12, and 18 months of therapy versus ES = 4.92 (CI 3.85, 5.86) 
baseline; P <0.001 versus controlled after 12 months
patients ES = 7.38 (CI 5.89, 8.68) 
after 18 months
DLCO: no change in Cyc group (P = NS), ES = 2.46 (CI 1.76, 3.1) 
worsening in AZA group (P <0.01) after after 6 months
6, 12, and 18 months of change in Cyc ES = 5.12 (CI 4.02, 6.09) 
group (P = NS), worsening in AZA group after 12 months
(P <0.001) after 12 and 18 months of ES = 7.72 (CI 6.16, 9.07) 
therapy versus baseline; P <0.001 versus after 18 months
controlled patients
AZA, azathioprine; CI, confidence interval; Cyc, cyclophosphamide; DLCO, diffusing lung capacity for carbon monoxide; ES, effect size; FEV1,
forced expiratory volume in 1 second; FVC, forced vital capacity; HAQ-DI, Health Assessment Questionnaire-Disability Index; HRCT, high-
resolution computed tomography; Kco, monoxide transfer coefficient; MRSS, modified Rodnan skin score; NNH, number needed to harm; NNT,
number needed to treat; NS, not significant; SF-36, short form-36; TLC, total lung capacity.
patients in whom a recent decrease of more than 10% in
FVC and/or DLCO has occurred either with or without the
development of new symptoms, mainly dyspnoea on exertion.
The third fact is that the studies have focused their attention
on diffuse SSc patients only, whereas limited SSc patients
with ILD are not usually targeted in trials.
Besides efficacy, there is still concern about the use of CYC
for the occurrence of adverse events. In fact, according to the
scleroderma lung study group, basing the analysis on a case
with a history of SSc ILD of 1.5 years, the treatment-related
toxicity seems to be higher than the beneficial effect. How-
ever, when the authors performed a sensitive analysis that
also considered a treatment initiation after 0.7 and 3 years
from the diagnosis, they demonstrated that an early initiation
of the treatment was associated with a greater preservation
of lung function and that it allowed a gain of 0.20 quality-
adjusted life years (QALYs) versus a loss of 0.21 QALYs of
the case base (disease duration of 1.5 years) and 0.44
QALYs if started after 3 years from the diagnosis [9]. These
data clearly demonstrate that an early diagnosis of ILD in SSc
is fundamental for starting a treatment that may ameliorate
quality of life and increase survival.
We know that the gold standard to assess the efficacy of a
drug is an RCT and therefore the only way to lift the curtain
on the role of CYC in ILD will derive from a trial on patients
with properly defined early and active SSc. The absence of
guidelines derived from RCT leaves the treatment in the
hands of physicians who almost bare-handedly are still
confronted with the challenge of blocking the evolution of
SSc and of ILD [10]. The increasing awareness and
knowledge of SSc pathogenesis, the development of
international networks (European League Against
Rheumatism Scleroderma Trials And Research [EUSTAR]
group), and the fact that new promising drugs
(mycophenolate and kinase inhibitors) and treatment
strategies (hematopoietic stem cell transplantation) are now
under scrutiny in RCTs indicate that we are just at the dawn
of a new era that likely will lead to the identification of
therapies able to consistently slow the eventual evolution of
SSc to fibrosis and atrophy.
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